Search

Pretomanid

Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens. … Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern.

Denosumab

Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women.

Dapagliflozin

[A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. … [L48251] It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April

Mangafodipir

This drug is made up of paramagnetic manganese (II) ions combined with the chelating agent _fodipir_ (dipyridoxyl diphosphate, DPDP). … Manganese absorption into the tissues that makes the normal tissue appear brighter in MRI is limited in abnormal or cancerous tissue.

(+)-menthol

Lovastatin

[A181087, A181406] Lovastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [simvastatin] are considered first-line … were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while lovastatin has been found to have an average decrease in LDL-C of 25-40%.

Capivasertib

Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative

Nilotinib

A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.

Trovafloxacin

It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. … It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones.